| Summary of 2016 Guidelines Changes and Highlights |
- Lipid screening for both men and women ≥ 40 years of age
- Inclusion of screening for women with a history of hypertensive diseases of pregnancy
|
- Non-fasting lipid determination recommendation
- LDL-C as primary, non-HDL-C or apoB as alternative targets
|
- Risk assessment with modified Framingham Risk Score to determine risk category
- Alternate approach is use of Cardiovascular Life Expectancy Model (CLEM) to calculate cardiovascular age
- Shared decision making
|
- Retention of treatment targets for those on therapy
- Broader treatment recommendations for those in intermediate risk category
- New expanded definition of CKD as high risk phenotype
|
- Statins remain drugs of choice
- New recommendation for non-statin drugs
|
- Nutritional guidelines that focus on dietary patterns – Mediterranean, DASH or Portfolio diet
- Detailed review of the impact of nutritional components on lipids and CV events
|